Core Insights - Sanofi has received conditional marketing authorization from the European Commission for Rezurock (belumosudil) to treat chronic graft-versus-host disease (GVHD) in adults and children aged 12 years and above weighing at least 40 kg, pending the completion of a confirmatory study [1][2][4] Group 1: Approval Details - The approval in the EU was anticipated following a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in January 2026 [2] - Rezurock's approval is based on safety and efficacy data from various clinical studies, including the phase II ROCKstar study, which demonstrated clinically meaningful and durable responses in patients with chronic GVHD after stem cell transplant [4][6] Group 2: Sales Performance - Rezurock sales increased by 8.7% year-over-year in 2025, amounting to €490 million, with expectations for further growth following the EU approval [6][7] - The approval is expected to drive additional sales growth in 2026 as Sanofi continues to evaluate Rezurock's safety and efficacy in other age groups and indications [8] Group 3: Market Context - Year to date, Sanofi's shares have declined by 3.8%, which is a smaller decrease compared to the industry's decline of 4.7% [3]

Core Viewpoint - Sanofi's Rezurock (belumosudil) has received conditional marketing authorization in the EU for treating chronic graft-versus-host disease (GVHD) in adults and children aged 12 years and older, addressing a significant unmet medical need for patients with limited treatment options [1][2][4] Group 1: Approval and Indications - The European Commission granted conditional marketing authorization for Rezurock for chronic GVHD in patients aged 12 years and older with a body weight of at least 40 kg [1] - The approval is contingent on the completion of a confirmatory randomized controlled study, following a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use [1][2] - Rezurock is already approved in 20 countries, including the US, UK, and Canada, for patients 12 years and older who have failed at least two prior lines of systemic therapy [4] Group 2: Clinical Evidence and Efficacy - The approval is based on safety and efficacy results from multiple clinical studies, including the ROCKstar phase 2 study, which showed clinically meaningful and durable responses in patients with chronic GVHD after stem cell transplant and at least two prior lines of systemic therapy [2][9] - The ROCKstar study demonstrated a best overall response rate (ORR) of 74% with Rezurock treatment, indicating significant efficacy [9] - Treatment was generally well tolerated, with common adverse reactions including fatigue (46%), diarrhea (35%), and nausea (35%) [9] Group 3: Commitment to Research and Development - Sanofi is committed to assessing the safety and efficacy of Rezurock in other age groups and indications, including ongoing studies for pediatric patients with chronic GVHD from one year old [6] - The company aims to expand the therapeutic applications of Rezurock, including for patients with chronic lung allograft dysfunction, which are currently in clinical studies [6]

Core Viewpoint - Sanofi's Rezurock (belumosudil) has received conditional marketing authorization in the EU for treating chronic graft-versus-host disease (GVHD) in adults and children aged 12 years and older, providing a new treatment option for patients with limited alternatives [1][2] Group 1: Approval and Indications - The European Commission granted conditional marketing authorization for Rezurock for chronic GVHD in patients aged 12 years and older with a body weight of at least 40 kg [1] - The approval is contingent on the completion of a confirmatory randomized controlled study, following a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use [1][2] - Rezurock is also approved in 20 countries, including the US, UK, and Canada, for patients 12 years and older after failure of at least two prior lines of systemic therapy [4] Group 2: Clinical Evidence and Efficacy - The approval is based on safety and efficacy results from several clinical studies, including the ROCKstar phase 2 study, which showed clinically meaningful and durable responses in patients with chronic GVHD after stem cell transplant and at least two prior lines of systemic therapy [2][9] - The ROCKstar study demonstrated a best overall response rate (ORR) of 74% with Rezurock treatment, indicating significant efficacy [9] - Treatment was generally well tolerated, with common adverse reactions including fatigue (46%), diarrhea (35%), and nausea (35%) [9] Group 3: Commitment to Research and Development - Sanofi is committed to assessing the safety and efficacy of Rezurock in other age groups and indications, including ongoing studies for pediatric patients with chronic GVHD from one year old [6] - The company aims to expand the therapeutic applications of Rezurock, indicating a strong focus on research and development in the field of chronic GVHD [6]

Core Viewpoint - Sanofi's Rezurock (belumosudil) has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for conditional marketing authorization in the EU to treat chronic graft-versus-host disease (GVHD) in adults and children aged 12 years and older with a body weight of at least 40 kg, particularly when other treatment options are limited or exhausted [1][2][7] Group 1: Clinical Efficacy and Safety - The CHMP's recommendation is based on safety and efficacy results from multiple clinical studies, including the ROCKstar phase 2 study, which showed a best overall response rate (ORR) of 74% among patients treated with Rezurock after at least two prior lines of systemic therapy [6][9] - Treatment with Rezurock was generally well tolerated, with common adverse reactions including fatigue (46%), diarrhea (35%), nausea (35%), dyspnea (32%), cough (30%), and upper respiratory tract infections (26%) [9] Group 2: Market Context and Future Steps - Rezurock is already approved in 20 countries, including the US, UK, and Canada, for patients aged 12 years and older who have failed at least two prior lines of systemic therapy, and in China after failure of one prior line [3] - Sanofi is committed to conducting a new post-approval confirmatory study to further investigate Rezurock's efficacy and safety, addressing the limited treatment options available for EU patients with chronic GVHD [2][5] Group 3: Disease Impact - Chronic GVHD is a severe complication following stem cell transplants, affecting up to 50% of patients and leading to significant morbidity and late non-relapse mortality [10] - The disease can severely impact patients' daily lives, limiting activities and imposing an emotional toll, highlighting the need for effective treatment options like Rezurock [2][10]

Core Viewpoint - Sanofi's Rezurock (belumosudil) has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for conditional marketing authorization in the EU to treat chronic graft-versus-host disease (GVHD) in adults and children aged 12 years and older with a body weight of at least 40 kg, particularly when other treatment options are limited or exhausted [1][2][7] Group 1: Clinical Efficacy and Safety - The CHMP's recommendation is based on safety and efficacy results from multiple clinical studies, including the ROCKstar phase 2 study, which showed a best overall response rate (ORR) of 74% among patients treated with Rezurock after at least two prior lines of systemic therapy [6][9] - Treatment with Rezurock was generally well tolerated, with common adverse reactions including fatigue (46%), diarrhea (35%), nausea (35%), dyspnea (32%), cough (30%), and upper respiratory tract infections (26%) [9] Group 2: Market Context and Future Steps - Rezurock is already approved in 20 countries, including the US, UK, and Canada, for patients aged 12 and older who have failed at least two prior lines of systemic therapy, and in China after failure of one prior line [3] - Sanofi is committed to conducting a new post-approval confirmatory study to further investigate Rezurock's efficacy and safety, addressing the limited treatment options available for EU patients with chronic GVHD [2][5]

Core Viewpoint - Sanofi received a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding the marketing authorization application for Rezurock (belumosudil) for treating chronic graft-versus-host disease (cGVHD) in adults and pediatric patients, and the company plans to seek a re-examination of this opinion [1][3]. Group 1: Product Information - Rezurock is a first-in-class selective ROCK2 inhibitor, currently approved in 20 countries, including the US, UK, and Canada, for patients aged 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy [4][5]. - Since its first approval in the US in July 2021, more than 17,000 patients with cGVHD worldwide have been prescribed Rezurock [4]. Group 2: Clinical Evidence - The efficacy and safety of Rezurock are supported by several clinical studies, including the randomized, multicenter ROCKstar phase 2 study, which demonstrated consistent efficacy and tolerability for patients with cGVHD, as well as durable clinical responses over a period of three years [3][4]. Group 3: Impact of cGVHD - cGVHD is a life-threatening complication affecting up to 50% of patients who undergo stem cell transplants, and it is a major cause of morbidity and late non-relapse mortality following such procedures [2][6].